VasicinoneCAS# 486-64-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 486-64-6 | SDF | Download SDF |
| PubChem ID | 442935 | Appearance | White powder |
| Formula | C11H10N2O2 | M.Wt | 202.2 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in chloroform and ethanol; insoluble in water | ||
| Chemical Name | (3S)-3-hydroxy-2,3-dihydro-1H-pyrrolo[2,1-b]quinazolin-9-one | ||
| SMILES | C1CN2C(=NC3=CC=CC=C3C2=O)C1O | ||
| Standard InChIKey | SDIVYZXRQHWCKF-VIFPVBQESA-N | ||
| Standard InChI | InChI=1S/C11H10N2O2/c14-9-5-6-13-10(9)12-8-4-2-1-3-7(8)11(13)15/h1-4,9,14H,5-6H2/t9-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Vasicinone may act as a hepatoprotective agent. 2. (±)-Vasicinone has significant antitussive, expectorant, and bronchodilating activities, which can be used to treat respiratory disease. 3. (S)-Vasicinone exhibits antiproliferative activity against human gastric cancer cells MCG-803. |
| Targets | P450 (e.g. CYP17) |
Vasicinone Dilution Calculator
Vasicinone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.9456 mL | 24.728 mL | 49.456 mL | 98.912 mL | 123.64 mL |
| 5 mM | 0.9891 mL | 4.9456 mL | 9.8912 mL | 19.7824 mL | 24.728 mL |
| 10 mM | 0.4946 mL | 2.4728 mL | 4.9456 mL | 9.8912 mL | 12.364 mL |
| 50 mM | 0.0989 mL | 0.4946 mL | 0.9891 mL | 1.9782 mL | 2.4728 mL |
| 100 mM | 0.0495 mL | 0.2473 mL | 0.4946 mL | 0.9891 mL | 1.2364 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isoformononetin
Catalog No.:BCN8206
CAS No.:486-63-5
- Ononin
Catalog No.:BCN5926
CAS No.:486-62-4
- Bergaptol
Catalog No.:BCN5588
CAS No.:486-60-2
- (-)-Cotinine
Catalog No.:BCC7569
CAS No.:486-56-6
- (S)-Coclaurine
Catalog No.:BCN5585
CAS No.:486-39-5
- Daphnetin
Catalog No.:BCN1051
CAS No.:486-35-1
- Fraxinol
Catalog No.:BCN5584
CAS No.:486-28-2
- Isofraxidin
Catalog No.:BCN2327
CAS No.:486-21-5
- PMX 464
Catalog No.:BCC6348
CAS No.:485842-97-5
- Mirabijalone D
Catalog No.:BCN4071
CAS No.:485811-84-5
- Choline sulphate
Catalog No.:BCN1792
CAS No.:4858-96-2
- Proanthocyanidins
Catalog No.:BCN6313
CAS No.:4852-22-6
- Daidzein
Catalog No.:BCN5590
CAS No.:486-66-8
- Harman
Catalog No.:BCN3998
CAS No.:486-84-0
- N-Methylcytisine
Catalog No.:BCN1266
CAS No.:486-86-2
- alpha-Isolupanine
Catalog No.:BCN7989
CAS No.:486-87-3
- Anagyrine
Catalog No.:BCN3049
CAS No.:486-89-5
- Thermopsine
Catalog No.:BCN2603
CAS No.:486-90-8
- AZD2858
Catalog No.:BCC4509
CAS No.:486424-20-8
- CIQ
Catalog No.:BCC7862
CAS No.:486427-17-2
- O-Acetylcyclocalopin A
Catalog No.:BCN5586
CAS No.:486430-93-7
- Cyclocalopin A
Catalog No.:BCN5587
CAS No.:486430-94-8
- Citropten
Catalog No.:BCN4831
CAS No.:487-06-9
- Elemicin
Catalog No.:BCN2818
CAS No.:487-11-6
Antitumor quinazoline alkaloids from the seeds of Peganum harmala.[Pubmed:26166311]
J Asian Nat Prod Res. 2015 May;17(5):595-600.
A phytochemical study on the methanol extracts from the seeds of Peganum harmala L. led to a new quizonaline alkaloid (S)-Vasicinone-1-O-beta-d-glucopyranoside (1) and four known ones, (R)-Vasicinone-1-O-beta-d-glucopyranoside (2), (S)-Vasicinone (3), vasicine (4), and deoxyVasicinone (5). Their structures were elucidated by spectroscopic analysis including IR, HR-ESI-MS, 1D and 2D NMR, and specific rotation as well as by comparison of the data with those in the literature. All of the alkaloids were screened for antiproliferative activity against human gastric cancer cells MCG-803 with MTT method. Compounds 1 and 3 exhibited moderate inhibitory activity.
Antitussive, expectorant, and bronchodilating effects of quinazoline alkaloids (+/-)-vasicine, deoxyvasicine, and (+/-)-vasicinone from aerial parts of Peganum harmala L.[Pubmed:26547531]
Phytomedicine. 2015 Nov 15;22(12):1088-95.
BACKGROUND: The aerial parts of Peganum harmala L. (APP) is a well-known and effective herbal medicine in China, and has been commonly used for treating various ailments, including cough and asthma. OBJECTIVES: To evaluate the antitussive, expectorant, and bronchodilating effects of the quinazoline alkaloids (+/-)-vasicine (VAS), deoxyvasicine (DVAS) (both isolated from the alkaloid fraction of APP) and (+/-)-Vasicinone (VAO) (synthesized from VAS). METHODS: The three quinazoline alkaloids were tested as antitussive on cough models in mice and guinea pigs. VAO was synthesized from VAS via the oxidation of hydrogen peroxide. VAS, VAO, and DVAS were orally administered at dosages of 5, 15, and 45 mg/kg. Cough in these models was induced by ammonia, capsaicin, and citric acid. Phenol red secretion experiments in mice were performed to evaluate the expectorant activity of the alkaloids. Bronchodilating effects were evaluated by using a bronchoconstrictive induced by acetylcholine chloride and histamine in guinea pigs. RESULTS: In antitussive tests, VAS, VAO, and DVAS significantly inhibited coughing frequency and prolonged the cough latency period in animals. At the highest doses tested (45 mg/kg), they showed antitussive activities similar to codeine phosphate (30 mg/kg) in mice and guinea pigs. Expectorant evaluation showed that VAS, VAO, and DVAS could significantly increase phenol red secretion in mice by 0.54-, 0.79- and 0.97-fold, by 0.60-, 0.99-, and 1.06-fold, and by 0.46-, 0.73-, and 0.96-fold, respectively, at dosages of 5, 15, and 45 mg/kg compared with the control (0.5% CMC-Na, 20 ml/kg). Ammonium chloride at 1500 mg/kg increased phenol red secretion in mice by 0.97-fold compared with the control. Bronchodilation tests showed that VAS, VAO, and DVAS prolonged the pre-convulsive time for 28.59%, 57.21%, and 29.66%, respectively, at a dose of 45 mg/kg in guinea pigs, whereas aminophylline prolonged the pre-convulsive time by 46.98% compared with pretreatment. CONCLUSIONS: Quinazoline alkaloids VAS, VAO, and DVAS have significant antitussive, expectorant, and bronchodilating activities. VAS, VAO, and DVAS are the active ingredients in APP, which can be used to treat respiratory disease.
Evaluation of hepatoprotective activity of vasicinone in mice.[Pubmed:25059038]
Indian J Exp Biol. 2014 Jul;52(7):705-11.
Justicia adhatoda (vasaka) leaves have long been used in Indian Ayurvedic system of medicine as antitussive. Its crude extract has been previously reported to have hepatoprotective activity. Vasicinone was isolated from leaves of J. adhatoda, column purified and characterized using, TLC UV, FT-IR and 1H NMR. The isolated Vasicinone was evaluated for hepatoprotective activity using (CCl4)-induced acute hepatotoxicity model in mice. CCl4 treatments lead to significant increase in SGOT, SGPT, ALP levels. Pre-treatment with Vasicinone and silymarin (25 mg/kg/day for 7 days) significantly decreased these enzyme levels. Histopathology of the livers from Vasicinone and silymarin pre-treated animals showed normal hepatic cords and absence of necrotic changes suggesting pronounced recovery from CCl4 induced liver damage. Both Vasicinone and silymarin significantly decrease the CCl4 mediated increase in pentobarbital indiced sleeping time in experimental animals, thus indicating recovery of liver function. Based on the above results it can be concluded that Vasicinone may act as hepatoprotective in mice and warrants further investigation on human volunteers.
